Publication
Video
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Author(s):
In Partnership With:
Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the utility of BTK inhibitors in B-cell malignancies.
BTK inhibitors target an enzyme that is necessary for B-cell growth, says Leslie. Moreover, there are several approved indications for BTK inhibitors in chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma (MCL), and Waldenström macroglobulinemia.
Notably, ibrutinib (Imbruvica) and acalabrutinib (Calquence) are 2 BTK inhibitors that are approved for patients with B-cell malignancies. Moreover, zanubrutinib (Brukinsa) is currently approved in relapsed/refractory MCL and is the subject of ongoing investigation in other B-cell malignancies, Leslie concludes.
